Table 2: Effect (hazard ratio, HR) of clinical profiles and treatment on locoregional recurrence, distance recurrence, and death in breast cancer ( ), univariable analysis.

Prognostic factorsLocoregional recurrenceDistant recurrenceDeath
HR (95%CI) valueHR (95%CI) valueHR (95%CI) value

Age (year)
 >45 versus ≤450.91 (0.57–1.46)0.696
0.64 (0.44–0.94)0.022
1.01 (0.69–1.49)0.942
Types of surgery
 Simple mastectomy and BCS versus MRM0.85 (0.62–2.21)0.6091.41 (0.73– 2.70)0.3051.08 (0.62–1.88)0.792
Pathological tumor size (cm)
 >2 versus ≤21.85 (1.14–2.99)0.012
1.99 (1.30–3.04)0.001
2.12 (1.42–3.16)<0.001
Histological type
 Ductal CA versus lobular CA and other types5.04 (0.70– 36.19)0.1083.32 (0.82–13.44)0.0932.40 (0.76–7.54)0.135
Histological grade
 II and III versus I2.21 (1.06–4.59)0.0331.84 (1.01–3.35)0.0472.04 (1.15–3.63)0.015
Stage
 3 versus 1 and 23.56 (2.21–5.75)<0.0015.06 (3.43–7.46)<0.0014.53 (3.14–6.52)<0.001
Dissected axillary lymph nodes
 ≥10 versus <100.81 (0.49–1.34)0.408
0.86 (0.55–1.35)0.5140.81 (0.54–1.21)0.297
Positive axillary lymph nodes
 >3 versus ≤34.53 (2.89–7.10)<0.0014.93 (3.35–7.27)<0.0014.85 (3.39–6.92)<0.001
LVI
 Present versus absent3.42 (2.11–5.58)<0.0013.66 (2.40–5.59)<0.0014.35 (2.88–6.57)<0.001
Receptor status
 ER receptor
  Negative versus positive 1.49 (0.96–2.31)0.0792.05 (1.40–2.99)<0.0011.64 (1.15–2.34)0.006
 PR receptor
  Negative versus positive 1.24 (0.80–1.92)0.3391.84 (1.25–2.71)0.0021.57 (1.10–2.24)0.012
 HER2 receptor
  Negative versus positive0.60 (0.37–0.96)0.0330.89 (0.60–1.32)0.5530.80 (0.55–1.15)0.225
Treatment
 Radiotherapy
  Yes versus no2.17 (1.42–3.35)<0.0014.35 (2.93–6.47)<0.001
2.72 (1.91–3.86)<0.001
 Hormonal therapy
  Yes versus no0.64 (0.41–0.99)0.0440.45 (0.31–0.65)<0.0010.58 (0.41–0.82)0.002
 Chemotherapy
  Yes versus no3.78 (1.19–11.96)0.0242.99 (1.22–7.34)0.0170.97 (0.57–1.64)0.907

MRM: modified radical mastectomy; BCS: breast-conserving surgery; LVI: lymphovascular invasion; ER: estrogen receptor; PR: progesterone receptor; HER2: Human Epidermal Growth Factor Receptor 2.